Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | VBC101-F11 |
| Synonyms | |
| Therapy Description |
VBC101-F11 is a bispecific antibody-drug conjugate (ADC) that targets EGFR and MET, which potentially inhibits tumor growth (Cancer Res (2024) 84 (7_Supplement): LB043). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| VBC101-F11 | VBC101F11|VBC101 F11|VBC101|VBC 101|VBC-101 | EGFR Antibody 74 MET Antibody 39 | VBC101-F11 is a bispecific antibody-drug conjugate (ADC) that targets EGFR and MET, which potentially inhibits tumor growth (Cancer Res (2024) 84 (7_Supplement): LB043). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07136779 | Phase Ib/II | VBC101-F11 | First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies | Recruiting | USA | 0 |